Elan to lay off 230 in retooling

Embattled Irish drugmaker Elan plans to cut 230 positions, or 14 percent of its work force, as it postpones biologics manufacturing and realigns the R&D operations within its biopharmaceutical business. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.